Administration Protocols
Every Celexir therapy follows medically guided, EMA-aligned protocols—tailored by indication, optimized for bioavailability, and backed by clinical best practices. From peptides to exosomes, our administration methods ensure consistent, controlled, and patient-appropriate outcomes.
Administration Protocols
Therapeutic Delivery Backed by EMA-Regulated Standards
Clinical Use
Celexir’s regenerative therapies—including mesenchymal stem cells (MSCs), exosomes, and bioactive peptides—are administered via intravenous (IV), intramuscular (IM), subcutaneous, or localized delivery depending on clinical indication. All administration protocols are designed in accordance with the European Medicines Agency (EMA) guidelines for ATMPs, ensuring full compliance with:
EMA/CAT/571134/2009 Rev. 1: Guideline on quality, non-clinical and clinical requirements for ATMPs
GCP-compliant administration protocols
Patient safety monitoring standards
Risk-based approach to biodistribution and dose response
By aligning with EMA frameworks, we support both efficacy validation and regulatory acceptability in clinical and research applications across Europe.
Peptides & Exosomes
Celexir’s peptides and exosome therapies are administered through patient-friendly delivery systems that prioritize absorption, compliance, and pharmacokinetic stability:
Peptide Protocols: Most peptide therapies use a cyclical regimen — typically one month on, one month off — with daily subcutaneous administration via pre-filled, stabilized injectable pens.
GLP-1 analogues (e.g., Tirzepatide, Semaglutide): Administered weekly or biweekly, depending on clinical goals (e.g., weight loss, insulin sensitivity, metabolic enhancement).
Exosomes: Delivered either intravenously for systemic impact or intradermally for aesthetic and dermatological applications. Exosome therapy may be repeated every 4–6 weeks, based on therapeutic response and biomarker tracking.
These flexible, protocol-driven approaches allow practitioners to tailor treatment to each patient’s biological profile—while remaining consistent with best practices in regenerative and longevity medicine.